Presynaptic congenital myasthenic syndrome due to three novel mutations in SLC5A7 encoding the sodium-dependant high-affinity choline transporter.
Journal article
Rodríguez Cruz PM. et al, (2020), Neuromuscul Disord
Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure.
Journal article
Rodríguez Cruz PM. et al, (2020), Hum Mutat, 41, 619 - 631
Implementation of a genomic medicine multi-disciplinary team approach for rare disease in the clinical setting: a prospective exome sequencing case series
Journal article
Taylor J. et al, (2019), Genome Medicine, 11
β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
Journal article
Vanhaesebrouck AE. et al, (2019), Brain
The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies.
Journal article
Vanhaesebrouck AE. and Beeson D., (2019), Curr Opin Neurol, 32, 696 - 703
Muscle acetylcholine receptor conversion into chloride conductance at positive potentials by a single mutation.
Journal article
Cetin H. et al, (2019), Proc Natl Acad Sci U S A
Congenital myasthenic syndrome with mild intellectual disability caused by a recurrent SLC25A1 variant.
Journal article
Balaraju S. et al, (2019), Eur J Hum Genet
Paediatric myasthenia gravis: any prognostic factor for disease remission?
Conference paper
Vecchio D. et al, (2019), EUROPEAN JOURNAL OF NEUROLOGY, 26, 94 - 94
Testing the effects of SHP2 inhibition on in vitro and in vivo models of neuromuscular junction disorders
Conference paper
Cao M. et al, (2019), EUROPEAN JOURNAL OF NEUROLOGY, 26, 71 - 72
Rapsyn facilitates recovery from desensitisation in fetal and adult acetylcholine receptors expressed in a muscle cell line.
Journal article
Cetin H. et al, (2019), J Physiol
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations.
Journal article
Rodríguez Cruz PM. et al, (2019), Brain, 142, 1547 - 1560
Characterization of pathogenic monoclonal autoantibodies derived from muscle‐specific kinase myasthenia gravis patients
Journal article
Takata K. et al, (2019), JCI insight
A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era
Journal article
Thompson R. et al, (2018), Orphanet Journal of Rare Diseases, 13
Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design
Journal article
Dong YY. et al, (2018), Cell, 175, 1045 - 1058.e16
CONGENITAL MYASTHENIC SYNDROMES AND MYASTHENIA
Conference paper
Rodriguez Cruz P. et al, (2018), Neuromuscular Disorders, 28, S51 - S52
I.2New genes and better treatment for congenital myasthenic syndromes
Conference paper
Beeson D., (2018), Neuromuscular Disorders, 28, S29 - S29
SHP2 INHIBITION BY NSC-87877 RECOVERS THE PATHOGENIC IN VITRO EFFECTS OF MUSK-MG ANTIBODY SUBCLASSES
Conference paper
Cao M. et al, (2018), MUSCLE & NERVE, 58, S15 - S16
Mobility shift of beta-dystroglycan as a marker ofGMPPBgene-related muscular dystrophy
Journal article
Sarkozy A. et al, (2018), Journal of Neurology, Neurosurgery & Psychiatry, 89, 762 - 768
The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes
Journal article
Rodríguez Cruz P. et al, (2018), International Journal of Molecular Sciences, 19, 1677 - 1677
Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders
Journal article
Clausen L. et al, (2018), Journal of Neuromuscular Diseases, 5, 231 - 240